|Trial status||Trial open for recruitment|
Interventional with experimental drug
|Phase||Trial phase 1/2|
|Sponsor||Telix International Pty Ltd|
|Inclusion criteria||*Previously confirmed histological diagnosis of glioblastoma, with current clinical or imaging evidence for recurrence *Interval since end of 1st line XRT superior or equal to 6 months*Amino acid-based molecular imaging indicating pathologically increase|
The very latest radiotherapy equipment representing one more step on the road to perfecting our cancer treatment and the precision of our patient care.